Location Directory

Clinical trials in Tampa, Florida

This page shows live ClinicalTrials.gov search results for Tampa, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

2167

Shown on this page

Current sort

Institutions in Tampa

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Moffitt Cancer Center

Stored official records

Open in full search

Conditions: Heart Failure, NYHA Class II Heart Failure, NYHA Class III Heart Failure
Interventions: IVC Sensor; Device
Lead sponsor: Foundry Innovation & Research 1, Limited (FIRE1); Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 25
States / cities: Chula Vista, California • Sacramento, California • Jacksonville, Florida + 19 more

Conditions: COVID-19, SARS-COV-2 Infection
Interventions: BNT162b2 Vaccine, Placebo; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 5,240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 196
States / cities: Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 148 more

Conditions: Hidradenitis Suppurativa
Interventions: Placebo, SAR445399; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Scottsdale, Arizona • North Hollywood, California • Boynton Beach, Florida + 16 more

Conditions: Small-cell Lung Cancer
Interventions: Investigator's Choice of Therapy, ZL-1310; Drug
Lead sponsor: Zai Lab (Shanghai) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 37
States / cities: La Jolla, California • Sacramento, California • Aurora, Colorado + 30 more

Conditions: Ulcerative Colitis
Interventions: Duvakitug, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 37
States / cities: Tucson, Arizona • Coronado, California • Murrieta, California + 31 more

Conditions: Lung Cancer (Diagnosis)
Interventions: Standard medical treatment; Other
Lead sponsor: bioAffinity Technologies Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 2,063 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 11
States / cities: Palo Alto, California • Grand Junction, Colorado • Bay Pines, Florida + 7 more

Conditions: Biliary Tract Cancer (BTC), Epithelial Tumor, Locally Advanced, Lung Cancers, Metastatic Solid Tumors, Nasopharyngeal Cancers, Solid Tumor Cancer, Urothelial Cancer
Interventions: AVZO-1418, Combination Agent 1, Combination Agent 2; Drug
Lead sponsor: Avenzo Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 19
States / cities: Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 15 more

Conditions: Agitation, Alzheimer Disease
Interventions: KarX-EC, KarXT; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 42
States / cities: Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 37 more

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: AZD2275, AZD2284, AZD2287; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 12
States / cities: Palo Alto, California • San Diego, California • Miami, Florida + 9 more

Conditions: Refractory Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndromes, Relapsed Acute Myeloid Leukemia (AML), Relapsed Myelodysplastic Syndromes, Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Relapsed/Refractory AML
Interventions: AUTX-703; Drug
Lead sponsor: Auron Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Duarte, California • Tampa, Florida • Buffalo, New York + 6 more

Conditions: Moderately to Severely Active Crohns Disease
Interventions: Afimkibart, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 95
States / cities: Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 79 more

Conditions: Eosinophilic Asthma
Interventions: ICS-LABA, Placebo for Benralizumab, benralizumab; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 20
States / cities: Sun City, Arizona • Tucson, Arizona • Inglewood, California + 17 more

Clinical trials in Tampa, Florida

Filter and sort this location

Institutions in Tampa

Stored official records

NORM-HF Pivotal Study

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment